Medicine
Carbidopa and Levodopa 25 mg/250 mg tablet
Carbidopa and Levodopa 25 mg/250 mg tablet is a generic prescription medicine for oral use, made by 19 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20º to 25ºC (68º to 77ºF), excursions permitted to 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Carbidopa and Levodopa
- Brand
- Sold under the generic name
- Strength
- 25 mg/250 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 500 tablets, 1000 tablets and 48 more
- Manufacturers
- Aurobindo PharmaIndiaCamber PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaSun Pharmaceutical IndustriesIndiaAdvagen PharmaBryant Ranch PrepackScieGen PharmaceuticalsCouplerTeva PharmaceuticalsTruPharma19 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20º to 25ºC (68º to 77ºF), excursions permitted to 15° to 30°C (59° to 86°F). Store in a tightly closed container, protected from light and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N04BA02 Carbidopa and Levodopa
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 May 2021
- Identifiers
- RxCUI 197443, 197444, 197445DailyMed set ID 770ba054-fec4-4833-8096-85c3ce3ae830, 0c630a24-dc51-4601-a5d6-2f9e397a0449, 11e706c4-433c-1ea6-e063-6294a90ad360 +19NDC 31722-383, 72865-363, 42291-488 +19Application ANDA218939, ANDA074260, ANDA073607 +4
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
A sample of 40 packs from 19 labelers. The register lists 51 packs for this generic presentation, and we confirm the exact pack on the quote.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 59651-458-01 | Aurobindo PharmaIndia | 28 November 2022 |
| 500 tablet in 1 bottle | 59651-458-05 | Aurobindo PharmaIndia | 28 November 2022 |
| 1000 tablet in 1 bottle | 59651-458-99 | Aurobindo PharmaIndia | 28 November 2022 |
| 100 tablet in 1 bottle | 31722-383-01 | Camber PharmaceuticalsIndia | 27 May 2025 |
| 500 tablet in 1 bottle | 31722-383-05 | Camber PharmaceuticalsIndia | 27 May 2025 |
| 1000 tablet in 1 bottle | 31722-383-10 | Camber PharmaceuticalsIndia | 27 May 2025 |
| 100 tablet in 1 bottle | 75907-021-01 | Dr. Reddy's LaboratoriesIndia | 1 May 2024 |
| 500 tablet in 1 bottle | 75907-021-05 | Dr. Reddy's LaboratoriesIndia | 15 March 2025 |
| 100 tablet in 1 bottle | 62756-985-01 | Sun Pharmaceutical IndustriesIndia | 12 August 2021 |
| 500 tablet in 1 bottle | 62756-985-02 | Sun Pharmaceutical IndustriesIndia | 12 August 2021 |
| 1000 tablet in 1 bottle | 72888-108-00 | Advagen Pharma | 1 April 2023 |
| 100 tablet in 1 bottle | 72888-108-01 | Advagen Pharma | 1 April 2023 |
| 500 tablet in 1 bottle | 72888-108-05 | Advagen Pharma | 1 April 2023 |
| 30 tablet in 1 bottle | 72888-108-30 | Advagen Pharma | 1 April 2023 |
| 100 tablet in 1 bottle | 50228-459-01 | ScieGen Pharmaceuticals | 7 May 2021 |
| 500 tablet in 1 bottle | 50228-459-05 | ScieGen Pharmaceuticals | 7 May 2021 |
| 1000 tablet in 1 bottle | 50228-459-10 | ScieGen Pharmaceuticals | 7 May 2021 |
| 30 tablet in 1 bottle | 50228-459-30 | ScieGen Pharmaceuticals | 7 May 2021 |
| 100 tablet in 1 bottle | 0093-9703-01 | Teva Pharmaceuticals | 5 March 2024 |
| 500 tablet in 1 bottle | 0093-9703-05 | Teva Pharmaceuticals | 15 December 2023 |
| 1000 tablet in 1 bottle | 0093-9703-10 | Teva Pharmaceuticals | 8 February 2024 |
| 1000 tablet in 1 bottle | 52817-392-00 | TruPharma | 4 April 2023 |
| 100 tablet in 1 bottle | 52817-392-10 | TruPharma | 4 April 2023 |
| 500 tablet in 1 bottle | 52817-392-50 | TruPharma | 4 April 2023 |
| 100 tablet in 1 bottle | 72865-363-01 | XLCare Pharmaceuticals | 19 January 2026 |
| 1000 tablet in 1 bottle | 72865-363-10 | XLCare Pharmaceuticals | 19 January 2026 |
| 30 tablet in 1 blister pack | 67046-1450-3 | Coupler | 7 February 2025 |
| 30 tablet in 1 blister pack | 67046-1668-3 | Coupler | 22 April 2026 |
| 30 tablet in 1 blister pack | 67046-1689-3 | Coupler | 13 July 2026 |
| 30 tablet in 1 bottle | 63629-4134-1 | Bryant Ranch Prepack | 7 April 2025 |
| 270 tablet in 1 bottle | 63629-4134-2 | Bryant Ranch Prepack | 7 April 2025 |
| 60 tablet in 1 bottle | 63629-4134-3 | Bryant Ranch Prepack | 7 April 2025 |
| 100 tablet in 1 bottle | 63629-9154-1 | Bryant Ranch Prepack | 27 January 2022 |
| 100 blister pack in 1 carton / 1 tablet in 1 blister pack | 60687-836-01 | American Health Packaging | 16 March 2024 |
| 100 tablet in 1 bottle | 42291-488-01 | AvKARE | 21 February 2024 |
| 1000 tablet in 1 bottle | 42291-488-10 | AvKARE | 21 February 2024 |
| 10 blister pack in 1 bag / 1 tablet in 1 blister pack | 55154-0192-0 | Cardinal Health | 10 October 2025 |
| 100 blister pack in 1 carton / 1 tablet in 1 blister pack | 0904-7549-61 | Major Pharmaceuticals | 28 April 2025 |
| 100 tablet in 1 bottle, plastic | 71205-879-00 | Proficient Rx | 5 November 2021 |
| 1000 tablet in 1 bottle, plastic | 71205-879-11 | Proficient Rx | 5 November 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Carbidopa and Levodopa
Clinical summary
Carbidopa and Levodopa is a fixed-dose combination medicine indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. MedsAcross supplies Carbidopa and Levodopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Carbidopa and LevodopaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SINEMET prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
- Hopledo: European public assessment report (EPAR) · European Medicines Agency
- Onerji: European public assessment report (EPAR) · European Medicines Agency
Need Carbidopa and Levodopa 25 mg/250 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.